17% Segment Profit Growth on 5% Revenue Growth: Healthcare Profit Has Moved Downstream, and at 18.3x You Already Pay for It

Cardinal Health grew pharmaceutical segment profit 17% on 6% revenue growth, lifts segment margin to 1.25% from 1.13% a year earlier. Management's guidance does the same thing one level up: pharmaceutical segment profit is now expected to grow 10% to 12% on revenue growth of only 3% to 5%. Profit dollars are compounding roughly three times faster than the revenue they ride on, which is what happens when the economics are per unit and per service rather than per list-price dollar.

The same quarter proves the point in the other direction. Global Medical Products and Distribution profit fell 28% to $33 million and margin slipped 41 basis points to 1.03% on currency and distribution costs, with sustained high petroleum prices pushing the segment toward the low end of its $200–$220 million fiscal 2027 guide. Delivery is not one business: specialty and GLP-1 volumes earn more, commodity-linked medical distribution earns less.

Nothing in the Sept. 30, 2026 quarter reflects the Jan. 1, 2027 negotiated prices. CMS set maximum fair prices for 15 Medicare Part D drugs for 2027; the three Novo Nordisk GLP-1s were repriced to $274 per 30-day supply from a $959 2024 list, a 71% cut, and CMS estimates the 15 prices save roughly $12 billion in net covered drug costs, about 44% below 2024 pricing, with $685 million of beneficiary out-of-pocket savings. For a manufacturer that is a price line. For a distributor it is a volume line — and volume is still growing.

The arithmetic is the whole argument. Cardinal Health earns a spread on units shipped and services rendered, so a lower list price per script compresses reported revenue without compressing profit dollars at the same rate — which is precisely why guidance now shows pharmaceutical segment profit up 10% to 12% on revenue up just 3% to 5%. The risk runs the other way, through volume rather than price: the 2027 Part D redesign lifts the standard deductible to $700 and the out-of-pocket cap to $2,400, and a plan that steers utilisation or shifts site of care changes the number of units a distributor touches.

Timing matters for the long view. The first wave sits in the middle of Cardinal's fiscal 2027, the second in the middle of fiscal 2028, and fiscal 2029 is the first year that carries both in full. That is the window in which a distributor's reported revenue and its profit pool can visibly diverge — and the window in which the multiple the market pays for that divergence gets tested.

The merger tape says the same thing more bluntly than the guidance. Since December 2024, the three largest U.S. distributors have committed roughly $20.4 billion of enterprise value to assets that deliver care rather than move boxes: home infusion, community oncology, gastroenterology, urology, and direct-to-patient diabetes supplies. None of these transactions buys a molecule, a patent or a price increase.

One number in the market narrative needs correcting: the Option Care Health take-private is not an 11.9x EBITDA deal. At a $5.8 billion enterprise value against Option Care's trailing EBITDA, it prices at roughly 13.7x — above where Cencora's shares trade, and inside the range of the distributors themselves. That is the point, not a contradiction of it. Capital is not paying up for drug pricing power; it is paying up for the assets that deliver the dose, the visit and the infusion, and it is paying up at a premium to the distributors that merely move them.

A delivery layer only works if the channel cooperates, and two things changed in 2026 that make the arrangement considerably more durable than the distribution label implies: a five-and-a-half-year contract extension with the largest downstream buyer, and a build-out of owned downstream assets that sit above the manufacturer and below the patient.

The downstream counterparty deserves more attention than it gets. On Nov. 4, 2026, CVS Health reported third-quarter revenue of $108.4 billion, adjusted EPS of $2.09 — up more than 30% — and raised full-year 2026 adjusted EPS guidance to at least $8. The shares fell 12.96% to $79.56. Two days later and in the same supply chain, Cardinal Health beat, raised, and closed 2.2% higher at $267.82. When the market punishes a payer's beat-and-raise while rewarding a distributor's, the market is making a statement about which link in the chain it believes will keep the economics.

Three things undercut the clean story, and one of them is the concentration that makes the delivery layer work.

And the concentration is real. CVS Health trades at 8.5x trailing EV/EBITDA with 2026 Medicare Advantage medical costs guided to a 90.5% loss ratio, and its preliminary 2027 profit guidance disappointed investors in August 2026. A contract running to June 2032 locks Cardinal's volume; it does not upgrade the credit of the counterparty, and a $81.33 share price sitting far below a $115.52 consensus target is the market's own view of that credit.

Healthcare profit is migrating downstream, and Cardinal's September quarter is the cleanest evidence yet: profit dollars grew roughly three times faster than the revenue they rode on, in the same three months that CMS prepared to cut one manufacturer's list price by 71%. Capital is following the same logic with cheques rather than words — roughly $20.4 billion of delivery-layer enterprise value since December 2024, in a policy environment that makes drug pricing a political variable and care delivery a service business. The uncomfortable part is the entry point. Cardinal is no longer the cheap way to own this: 18.3x trailing EV/EBITDA against Cencora's 11.6x, about 20.8x the midpoint of its own raised guidance, with the same quarter containing a 28% profit decline in medical distribution and a $7.2 billion build that is mostly goodwill. The thesis is sound; the price on the best-positioned name is not.